News

Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory

INDIANAPOLIS, Aug. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-2 trial, evaluating orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes. In the trial,... Continue Reading

Repatha® now approved for adults at risk of major cardiovascular events from high LDL-C

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low Continue Reading

Heart Failure Society of America and American Society for Preventive Cardiology Joint Statement

WASHINGTON, Aug. 13, 2025 /PRNewswire/ -- Heart failure affects more than 6 million Americans and is projected to reach over 11 million by 2050. Despite therapeutic advances, nearly 1 in 4 patients are readmitted within 30 days of discharge and 1 in 5 dies within a year. The economic burden exceeds Continue Reading

Lilly’s Mounjaro (tirzepatide) showed cardiovascular protection in a landmark trial

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease Continue Reading

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option

PRINCETON, N.J.--(BUSINESS WIRE)-- The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) – (Pfizer NYSE: PFE) Alliance today announced a new direct-to-patient option for purchasing Eliquis® (apixaban) via our Alliance’s patient resource Eliquis 360 Support. The offering provides an... Continue Reading

ASPC Announces New Editor-in-Chief for American Journal of Preventive Cardiology

HOUSTON, July 15, 2025 /PRNewswire/ -- The American Society for Preventive Cardiology (ASPC) is thrilled to announce that the American Journal of Preventive Cardiology (AJPC), a leading publication in Cardiology, has appointed Dr. Khurram Nasir as its new Editor-in-Chief, effective January 1,... Continue Reading

Heartflow Plaque Analysis Awarded First Coverage Recommendation by Radiology Benefits Manager

MOUNTAIN VIEW, Calif. — July 11, 2025 — Heartflow, Inc., the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Analysis will be included in updated cardiac imaging guidelines by radiology benefit manager EviCore, which provides coverage... Continue Reading

Preventive Cardiology Takes Center Stage at ASPC 2025

This August, Boston will host one of the most influential gatherings in cardiovascular medicine as the American Society for Preventive Cardiology (ASPC) convenes its 2025 Congress on Cardiovascular Disease Prevention. Continue Reading

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies

PASADENA, Calif.--(BUSINESS WIRE)--Jun. 23, 2025-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company’s global Phase 3 clinical studies designed to support regulatory submissions for marketing... Continue Reading

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high CV risk

INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a definitive agreement for Lilly to acquire Verve. Read more... Continue Reading

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials

INDIANAPOLIS, June 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month through LillyDirect's Self Pay Pharmacy Solutions and... Continue Reading

ALYKA Health now a Supporting Partner of the American Society for Preventive Cardiology

ATLANTA, GA, UNITED STATES, June 16, 2025 /EINPresswire.com/ -- ALYKA Health, a digital health company that partners with providers to empower patients to improve their cardiovascular health and outcomes, announced that it is now a supporting partner of the American Society for Preventive... Continue Reading